Zobrazeno 1 - 10
of 52
pro vyhledávání: '"35"'
Autor:
Patricia A. Thompson, Michelle Turner, Carolyn Mies, Jules Cohen, Caterina Vacchi-Suzzi, Alison Stopeck, Lea N. Baer, Christina Preece, Christy A. Russell, Rebecca Batiste, Julie Anne L Gemmill
Publikováno v:
Cancer Research. 81:PS5-37
Background: Identifying when to start CDK4/6 inhibitors or use chemotherapy in hormone receptor positive (HR+) metastatic breast cancer (MBC) remains challenging. The 21-gene Oncotype DX Breast Recurrence Score® test is validated to predict chemothe
Publikováno v:
Cancer Research. 80:P1-20
Purpose: Recently, some studies confirmed that the surgical margin in patients with breast fibromatosis was not associated with recurrence. Wide tumor-free resection surgery, which used to be the first-line treatment, might not be necessary for all f
Autor:
Nancy Tray, Karen Hiotis, Deborah Axelrod, Victor Ty, Judith D. Goldberg, Farbod Darvishian, Maryann Kwa, Yelena Novik, Sylvia Adams, Amber A. Guth, James L. Speyer, Adriana Heguy, Douglas K. Marks
Publikováno v:
Cancer Research. 80:OT1-01
BACKGROUND: Receptor activator of NF-kB (RANK) and its ligand (RANKL) have a well-established role in osteoclast-driven bone remodeling, however RANK/RANKL expression can also be seen on mammary epithelial cells and immune cells (IC). In breast cance
Publikováno v:
Cancer Research. 75:P1-10
Introduction: With a reported incidence of 2-12% in breast biopsy specimens, the appropriate management of atypical ductal hyperplasia (ADH) remains in evolution. At present, the optimal screening guidelines for patients with high-risk breast lesions
Autor:
Masakazu Toi, Zhipeng Wang, Kazuharu Shimizu, Norikazu Masuda, Takayuki Ueno, Yoshiki Mikami, Fumiaki Sato, Akira Myomoto, Satoko Takizawa, Gozoh Tsujimoto
Publikováno v:
Cancer Research. 72:P5-10
[Background and Aim] Although Trastuzumab has been used for HER2(+) breast cancer, the treatment response of Trastuzumab therapy depends on unknown mechanisms among individual cases. In order to avoid unnecessary adverse events and to lighten financi
Autor:
Min-Hsien Wu, Siou-Ru Ye, Hung-Ming Wang, Ting-Hsiuan Yeh, Jason Chia-Hsun Hsieh, Jane Ying-Chieh Lee, Yung-Chang Lin, Nina Ming-Jung Lin
Publikováno v:
Cancer Research. 77:3790-3790
Background: Circulating tumor cell (CTC) has been prognostic and predictive in numerous types of cancer; however, its role in early diagnosis of relapse remains unclear. Methods: Eighty-six patients were prospectively enrolled between March 2015 and
Autor:
Tiffany Greenwood, Meiyappan Solaiyappan, Xingde Li, Zaver M. Bhujwalla, Kristine Glunde, Jiang Lu, Samata Kakkad
Publikováno v:
Cancer Research. 74:LB-160
The extracellular matrix (ECM) in breast cancers is altered and provides new biomarkers for cancer diagnosis [1] and prognosis [2,3]. Collagen I (Col1) fibers are the major ECM component in breast tumors, and increased Col1 has been found to facilita
Autor:
Jane Wei, Jodi M. Carter, Laila Khazai, Laura J. van't Veer, Molly Klein, Gregor Krings, Dina Kokh, Kimberly Cole, Yunn-Yi Chen, Lamorna Brown-Swigart, Ronald Balassanian, Sara J. Venters, Laura J. Esserman, Bev Parker, Amy L. Delson, Christina Yau, Sunati Sahoo, W. Fraser Symmans, Denise M. Wolf
Publikováno v:
Cancer Research. 80:P6-10
Background: The I-SPY 2 TRIAL enrolls women with locally advanced, molecular high-risk breast cancer. An integrated Residual Cancer Burden (iRCB), based on MRI volume change through treatment, is used to predict pathologic complete response (pCR) in
Autor:
Whitney A Sipe, Ujwala D Rajgopal, Michael J. Cross, Cary S. Kaufman, Kelly A Pierce, Katherine E Rankin, Gail Lebovic
Publikováno v:
Cancer Research. 80:P4-13
Introduction: Standard wire localization has long been the standard of care to assist surgeons with locating and excising non-palpable breast lesions identified by imaging. Significant challenges include scheduling conflicts, delays in surgery, accur
Autor:
Fumiaki Sato, Zhipeng Wang, Takayuki Ueno, Akira Myomoto, Satoko Takizawa, Feng Ling Pu, Norikazu Masuda, Yoshiki Mikami, Kazuharu Shimizu, Shigehira Saji, Masakazu Toi
Publikováno v:
Cancer Research. 73:1937-1937
[Background and Aim] Although Trastuzumab has been used for HER2(+) breast cancer, the treatment response of Trastuzumab therapy depends on unknown mechanisms among individual cases. In order to avoid unnecessary adverse events and to lighten financi